AstraZeneca Seeking to Link Executive Pay to $45 Billion TargetBy
Firm looking how to link long-term incentives to sales goal
Sunday Times said 20% of shareholders may reject CEO package
A board committee at AstraZeneca Plc is looking at ways to more clearly link executive compensation to a $45 billion revenue target amid reports of investor concern over the pay package of Chief Executive Officer Pascal Soriot.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.